A Phase I Open-Label Clinical Trial Evaluating the Therapeutic Vaccine hVEGF26-104/RFASE in Patients with Advanced Solid Malignancies.

ABSTRACT:

Lessons learned

The novel therapeutic vaccine hVEGF_26-104 /RFASE was found to be safe and well tolerated in patients with cancer. hVEGF_26-104 /RFASE failed to induce seroconversion against native hVEGF₁₆₅ and, accordingly, neither a decrease in circulating vascular endothelial growth factor (VEGF) levels nor clinical benefit was observed. Remarkably, hVEGF_26-104 /RFASE induced VEGF₁₆₅ -neutralizing antibodies in a nonhuman primate model. The absence of seroconversion in human calls for caution in the interpretation of efficacy of human vaccines in nonhuman primates.

Background

Targeting vascular endothelial growth factor-A (VEGF) is a well-established anticancer therapy. We designed a first-in-human clinical trial to inv

SUBMITTER: Goedegebuure RSA 

PROVIDER: S-EPMC7873342 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature